Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

PHASE3CompletedINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

February 11, 2020

Primary Completion Date

April 20, 2022

Study Completion Date

June 22, 2022

Conditions
Atopic Dermatitis
Interventions
BIOLOGICAL

Lebrikizumab

Subcutaneous injection

Trial Locations (70)

2606

Woden Dermatology, Phillip

3002

Sinclair Dermatology, East Melbourne

3052

Royal Childrens Hospital Melbourne, Parkville

4102

Veracity Clinical Research Pty Ltd, Woolloongabba

4217

The Skin Centre, Benowa

6009

Captain Stirling Medical Centre, Nedlands

11415

Forest Hills Dermatology Group, Kew Gardens

13601

Advanced Asthma and Allergy, Watertown

19103

Paddington Testing Company Inc, Philadelphia

20850

Dermatology and Skin Cancer Specialists, Rockville

22015

PI-Coor Clinical Research, LLC, Burke

23502

Virginia Clinical Research, Inc., Norfolk

30328

Advanced Medical Research, Sandy Springs

31419

Georgia Skin & Cancer Clinic, Savannah

31707

Georgia Pollens Clinical Research Centers, Inc, Albany

32073

Park Avenue Dermatology, Orange Park

32256

Solutions Through Advanced Research, Inc., Jacksonville

33021

Encore Medical Research, Hollywood

33134

C&R Research Services USA, Coral Gables

Florida Academic Centers Research and Education, LLC, Coral Gables

33143

Well Pharma Medical Research Corp., Miami

33146

Pediatric Skin Research, LLC, Coral Gables

33157

Sanchez Clinical Research Inc, Miami

33173

Miami Dermatology and Laser Research, Miami

36207

Pinnacle Research Group, Anniston

40217

Skin Sciences, PLLC, Louisville

45414

Ohio Pediatric Research Association, Dayton

46250

Dawes Fretzin Clinical Research Group, LLC, Indianapolis

48706

Great Lakes Research Group, Inc., Bay City

49085

St Joseph Dermatology and Vein Clinic, Saint Joseph

60611

Northwestern University, Chicago

61761

Sneeze, Wheeze, & Itch Associates LLC, Normal

63117

Central Dermatology PC, St Louis

66614

Kansas Medical Clinic, Topeka

70112

Tulane Univ School of Med, New Orleans

72117

Arkansas Research Trials, LLC, North Little Rock

74136

Central States Research, Tulsa

Vital Prospects Clinical Research Institute, P.C., Tulsa

76011

Arlington Research Center, Inc, Arlington

77065

Encore Imaging & Medical Research, Houston

77497

Acclaim Dermatology, PLLC, Sugar Land

77598

Center for Clinical Studies, Webster

78041

Cutis Wellness Dermatology, Laredo

78213

Progressive Clinical Research, San Antonio

78218

Texas Dermatology and Laser Specialists, San Antonio

80112

IMMUNOe International Research Centers, Centennial

91303

Hope Clinical Research, Canoga Park

92123

University of California, San Diego/Rady Children's Hospital, San Diego - Pediatric & Adolescent Dermatology, San Diego

92701

Southern California Dermatology, Inc., Santa Ana

92708

First OC Dermatology, Fountain Valley

MD Studies, Fountain Valley

95825

Integrative Skin Science and Research, Sacramento

33613-1244

ForCare Clinical Research, Tampa

03801

ALLCUTIS Research, Portsmouth

02010

The Skin Hospital, Sydney

06100

Burswood Dermatology, Victoria Park

T3A 2N1

Institute for Skin Advancement, Calgary

T4N 6V7

CARe Clinic, Red Deer

L3P 1X3

Lynderm Research Inc., Markham

L6J7W5

The Centre for Clinical Trials, Inc, Oakville

M5A3R6

AvantDerm, Toronto

30-033

"Grazyna Pulka Specjalistyczny Osrodek ALL-MED", Krakow

31-559

Diamond Clinic, Krakow

02-625

Centrum Medyczne Evimed, Warsaw

38-440

"Zespol Naukowo - Leczniczy Iwolang Sp. z o.o.", Iwonicz-Zdrój

40-611

Provita Sp. z o.o, Katowice

20-081

Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie, Lublin

50-566

CityClinic Przychodnia Lekarsko-Psychologiczna, Wroclaw

90-436

Dermoklinika Centrum Medyczne s.c. M. Kierstan J. Narbutt A. Lesiak, Lodz

25-155

Gabinet Dermatlogiczny. Beata Krecisz, Kielce

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Dermira, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT04250350 - Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter